Articles On Recce Pharmaceuticals (ASX:RCE)

Recce Pharmaceuticals (RCE) has multiple trials in the pipeline following the September quarterRCE reported no serious adverse effects in the seventh cohort who were dosed with 6000mg of its R327 drug and the positive outcomes will see a ph...

It’s Tuesday afternoon, and after a long, hard day buying and selling bits of paper that say you own small portions of much larger things, you owe it to yourself to sit back and relax in front of a warm, crackling fire. So crack open a bott...

Recce Pharmaceuticals (RCE) reports that independent studies of its RECCE 327 (R327) product found the drug to significantly reduce SARS-CoV-2 in Syrian golden hamstersThe company says the study results provide it with proof of concept that...

Highlights: The ASX 200 benchmark index closed up today, gaining 0.41% to end at 6,496.20 points. Over the last five days, the index has lost 4.56% and has shed 12.03% over the last 52 weeks. Materials was the best performing sector,...

Recce Pharmaceuticals (RCE) updates its clinical timeline, with several data read-outs expected over this year and next yearThe company expects to dose its first subject under a phase 1b/2a multi-dose and early-stage sepsis study later this...

PYC Therapeutics and Race Oncology announce new RNA programs Recce Pharma accelerates its clinical programs Orthocell gets first purchase orders The race is hotting up to develop the next RNA-based drug discovery, as a couple of ASX liste...

Reece Pharmaceuticals (RCE) will deliver the opening research and development address at the World Anti-Microbial Resistance (AMR) CongressThe Congress will take place today and tomorrow and is the world’s largest AMR conference with over 1...

Recce Pharmaceuticals (ASX:RCE) has announced the appointment of Dr John Prendergast as its executive chairman.

Highlights The ASX 200 benchmark index closed up today (5 September), gaining 0.34% to end at 6,852.20 points. Over the last five days, the index has lost 1.63% and it has plunged 8.92% over the last 52 weeks. Energy was the best perf...

Recce Pharmaceuticals (RCE) appoints Dr John Prendergast as Executive Chairman, effective immediatelyDr Prendergast has experience in commercialising pharmaceuticals for global markets, most notably the US, and has a background in microbiol...

Imaging specialist Clarity opens patient recruitment in Australia and will start Phase 2 trial soon Another imaging specialist Optiscan has made a FDA Pre-Market Notification 510(k) submission  Recce Pharma says dosing of Cohort 7 of its P...

Recce Pharmaceuticals (RCE) reports no serious adverse effects from intravenously dosing the seventh cohort of its phase one clinical trial with 6000 milligrams of its R327 drug As part of the trial, 10 healthy male subjects were dosed for...

The ASX is poised to open lower on Monday Wall Street ends a four-week winning streak last week Oil and gold also edge lower Local shares are set to open lower today. At 8am AEST, the ASX 200 September futures contract is pointing down by...

Recce Pharmaceuticals (RCE) progresses clinical trials of its R327 drug candidate during the June quarter One of the company’s standout moments for the period has been successfully dosing two cohorts with higher doses in its phase one intr...

Emerging Australian company Recce Pharmaceuticals (ASX:RCE) has appointed an experienced industry executive to lead the translation of its pipeline of anti-infectives.

Recce Pharmaceuticals (RCE) appoints Dr Philip Sutton as Vice President of Translational Sciences This role will take responsibility for advancing the company’s compounds across a portfolio of infectious disease programs with unmet medical...

A number of ASX shares in the S&P/ASX 200 Health Care Index (ASX: XHJ) outperformed the broader market today. The benchmark S&P/ASX 200 Index (ASX: XJO) backtracked yet again, ending Thursday’s session 1.97% lower at 6,568.1 poin...

Recce Pharmaceuticals jumps on positive safety data during trial dosing participants with anti-infective · Fenix Resources moves to full ownership ...

ShareCafeEvening Report: 21 June, 2022 by Melissa Darmawan   Australian shares snapped a seven-day losing streak led by resource and financial stocks amid the US futures pointing to a rise as Wall Street looks to resume trade after a long w...

Recce Pharmaceuticals (RCE) reports positive safety data in ten male subjects who received 4000mg of Recce’s R327 product as part of a first-phase clinical trial The subjects are part of the sixth cohort to be intravenously dosed with R327...

ShareCafeLunch Report: 21 June, 2022 by Melissa Darmawan   The Australian sharemarket is set to snap a seven-day losing streak as investors were relieved that RBA governor Philip Lowe doesn’t see a local recession coming. At noon, the S&amp...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is rebounding after hitting a near multi-year low of 56 cents yesterday. This comes after the pharmaceutical company provided an update on its development of a new class of synthetic a...

21 Jun 2022 - A snapshot of the stocks on the move, featuring ResApp (ASX:RAP), Radiopharm Theranostics (ASX:RAD), and Reece Pharmaceuticals (ASX:RCE).

ResApp’s independent study of cough app falls short Recce Pharma completes Cohort 6 dosage in Phase 1 trial Proteomics secures exclusive biomakers license Smartphone-based respiratory diagnostic maker, ResApp Health (ASX:RAP), plunged by...

ShareCafeQueuing at the ATM: ASX small caps discover a handy source of funding ASX-listed small cap companies are flocking to the ATM for a ready source of cash, at a time and amount of their choosing. In this case, ATM does not refer to th...

Recce Pharmaceuticals (RCE) sees its clinical trial receive a good safety profile among ten healthy male subjects The company reported its drug, R327, demonstrated a good tolerability profile among ten male subjects who were intravenously...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Recce Pharmaceuticals (RCE) is set to administer its “high dose” cohort following its successful phase one clinical trial of R327 in the “low dose” cohort The 10 healthy human subjects administered with R327 in the “low dose” cohort showed...

Chimeric wants to accelerate its clinical trial readiness via a deal with WuXi Recce advances to higher dosing in Phase I clinical trial Proteomics engages experts to advance commercialisation Chimeric signs deal with WuXi Cell therapy sp...

Australia-based drug developer Recce Pharmaceuticals (RCE) granted a patent in Hong Kong for two of its synthetic polymer anti-infective drug candidates The patent is called the “Anti-Virus Agent and Method for Treatment of Viral Infection...

ResApp gets takeover offer from Pfizer Recce gets Hong Kong patent RhinoMed comes out of trading halt and rallied 20% Smartphone-based health company ResApp Health (ASX:RAP) surprised the market this morning after revealing that global gi...

Recce Pharmaceuticals (RCE) reports positive safety results from the fourth patient cohort in a first-phase trial of its RECCE 327 (R327) synthetic anti-infective The drug developer dosed 10 healthy male subjects with 1000mg of R327 as par...

Highlights Recce Pharmaceuticals’ R327 exhibits a safe and tolerable profile. The safety profile of R327 at a twenty-fold increase of the initial dosing level is crucial for synergies across the company’s wider-infectious disease portf...

The Tempest, a tale of love, revenge and family set at sea, is thought to be the last play that William Shakespeare wrote alone. One area it doesn’t touch on in detail is staggering riches; a theme now more relevant to shareholders in Tempe...

Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.

ASX-listed Recce Pharmaceuticals (RCE) has developed a synthetic anti-infective designed to not only kill bacteria and emerging viral pathogens but treat sepsis before it can take hold Sepsis is the leading cause of hospitalisation in the...

Recce Pharmaceuticals’ (RCE) new class of synthetic anti-infectives drug, the RECCE 327 (R327) has been given the go-ahead for the next set of doses by an Independent Safety Committee (ISC) following a successful Phase I intravenous (IV) c...

Highlights The ASX 200 was trading 0.31% up at 7,113.8 in the first 15 minutes of trading. Brent crude oil rallied sharply to over US$139 per barrel mark on Monday. The energy index was the top gainer, surging 4.69% in early trade....

The ASX 200 Health Index (XHJ) is trading lower by 1.40% at the time of writing, compared to the broader index which is down by 0.35%. Cell therapy specialist Chimeric Therapeutics (ASX:CHM) has just announced the final results of its Phase...

Recce Pharmaceuticals (RCE) doses the final three patients under cohort three of the Phase I intravenous (IV) clinical trial of RECCE327 (R327) The study is evaluating the safety and pharmacokinetics of R327 in seven to 10 subjects with do...

At the time of writing, the ASX 200 Health Index (XHJ) is down by 1.90%, while the benchmark ASX 200 has fallen by 0.3%. Genomics specialist Genetic Technologies (ASX:GTG) says that its laboratory in Fitzroy, Melbourne has received simultan...

“Completing this Cohort with the maximum number of subjects, sees R327 (500mg, I.V.) further a compelling Safety profile at a milestone dose. We anticipate recommendation to start dosing Cohort 4 at higher concentrations again in near weeks...

Recce Pharmaceuticals’ (RCE) phase-one intravenous clinical of R327 indicates a good safety and tolerability profile among seven healthy male subjects The company says its cohort three was tested with 500 mg of R327, which is designed for...

NeuroScientific Biopharmaceuticals (ASX:NSB) share price jumped ~13% today to 35 cents after an update on its lead drug candidate EmtinB. The company said it has executed on the successful completion of invitro genotoxicity and plasma prote...

According to PEW Charitable Trusts global antibiotic pipeline review, R327 is the only clinical-stage new class of antibiotic in the world being developed for sepsis, the largest unmet medical need in human health.

Recce Pharmaceuticals (RCE) ended the December quarter with a cash balance of $15.83 million post research and development (R&D) costs of $1.54 million During the quarter, Recce reported positive data from its phase 1 and 2 clinical t...

The ASX 200 posted a small 0.11 fall on Tuesday, outperformed by the small end of town as the microcap Emerging Companies index rose by 0.66%. There were no clear catalysts as Asian markets struggled for direction after Wall Street was clos...

Recce Pharmaceuticals (RCE) has released positive safety data from its second cohort of subjects for its Phase I intravenous clinical trial of RECCE 327 (R327) R327 is designed to treat serious bacterial infections including sepsis. The se...

Key Points The Recce share price is up 3.85% to $1.35 An independent safety committee has cleared stronger dosing of Recce 327 Trial subjects are expected to be recruited sometime this week The Recce Pharmaceuticals Ltd (ASX: RCE) share...